Floatz logo

Darinaparsin

Bone Marrow Neoplasms

Alaunos TherapeuticsSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Bone Marrow Neoplasms cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Darinaparsin is also rated in:

Peripheral T-cell LymphomaDormant
B
Indicative ·
58 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
B
Indicative ·
57 / 100
View asset →
plasma cell myelomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →